First-Line Enfortumab Vedotin Plus Pembrolizumab vs Gemcitabine Plus Cisplatin for Metastatic Urothelial - Top-Institutions - MDSpire

First-Line Enfortumab Vedotin Plus Pembrolizumab vs Gemcitabine Plus Cisplatin for Metastatic Urothelial

  • By

  • Eusebio Luna Velasquez

  • Renil S. Titus

  • David-Dan Nguyen

  • Carlos Riveros

  • Aly-Khan Lalani

  • Dharam Kaushik

  • Guru P. Sonpavde

  • Petros Grivas

  • Christopher J. D. Wallis

  • Raj Satkunasivam

  • July 1, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Mount Sinai Tisch Cancer Center
    Mount Sinai Tisch Cancer Center

    New York, NY

    Key Differentiators

    • Oncology

  • #2

    Barts Cancer Institute
    Barts Cancer Institute

    London, England

    Key Differentiators

    • Oncology

  • #3

    National Cancer Center Hospital East
    National Cancer Center Hospital East

    Kashiwa, Chiba

    Key Differentiators

    • Oncology

  • #4

    Hospital of the University of Pennsylvania
    Hospital of the University of Pennsylvania

    Philadelphia, PA

    Key Differentiators

    • Oncology

  • #5

    Perelman Center
    Perelman Center

    Philadelphia, PA

    Key Differentiators

    • Oncology

Original Source(s)

First-Line Enfortumab Vedotin Plus Pembrolizumab vs Gemcitabine Plus Cisplatin for Metastatic Urothelial

  • by Eusebio Luna Velasquez, Renil S. Titus, David-Dan Nguyen, Carlos Riveros, Aly-Khan Lalani, Dharam Kaushik, Guru P. Sonpavde, Petros Grivas, Christopher J. D. Wallis, Raj Satkunasivam

  • July 1, 2026

Related Content

Targeting the E2F6-TOP2A-DKK1 axis: a novel therapeutic strategy for EMT-driven hepatocellular carcinoma progression

ASCO26: Atish Choudhury, MD, PhD, A-DREAM/Alliance A032101

A-DREAM/Alliance A032101 study presented by Dana-Farber Cancer Institute's Dr. Atish Choudhury shows 41% of favorable responders to testosterone suppression plus androgen receptor pathway inhibitor remaining treatment-free with testosterone recovery at 18 months after treatment interruption.

  • July 1, 2026

  • 1 min
Editorial: National Colorectal Cancer Awareness Month 2025: Current Progress and Future Prospects on Colorectal Cancer Prevention, Diagnosis and Treatment